

Audit Review Table				
Blue Cross and Blue Shield of New Mexico (Org ID: 1825, Sub ID: 9522, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)				
Measurement Year - 2020; Date & Timestamp - 06/01/2021 5:18 PM				
This submission is on the stage: Import				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Effectiveness of Care				
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)				
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - BMI percentile (Total)		60.83%	R	Reported
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Nutrition (Total)		53.53%	R	Reported
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Physical Activity (Total)		50.36%	R	Reported
Childhood Immunization Status (CIS)				
Childhood Immunization Status - DTaP		78.1%	R	Reported
Childhood Immunization Status - IPV		91%	R	Reported
Childhood Immunization Status - MMR		90.75%	R	Reported
Childhood Immunization Status - HiB		90.02%	R	Reported
Childhood Immunization Status - Hepatitis B		90.02%	R	Reported
Childhood Immunization Status - VZV		89.54%	R	Reported
Childhood Immunization Status - Pneumococcal Conjugate		79.56%	R	Reported
Childhood Immunization Status - Hepatitis A		89.54%	R	Reported
Childhood Immunization Status - Rotavirus		75.91%	R	Reported
Childhood Immunization Status - Influenza		52.31%	R	Reported
Childhood Immunization Status - Combo 2		74.45%	R	Reported
Childhood Immunization Status - Combo 3		70.56%	R	Reported
Childhood Immunization Status - Combo 4		70.32%	R	Reported
Childhood Immunization Status - Combo 5		62.77%	R	Reported
Childhood Immunization Status - Combo 6		43.8%	R	Reported
Childhood Immunization Status - Combo 7		62.53%	R	Reported
Childhood Immunization Status - Combo 8		43.8%	R	Reported
Childhood Immunization Status - Combo 9		40.63%	R	Reported
Childhood Immunization Status - Combo 10		40.63%	R	Reported
Immunizations for Adolescents (IMA)				
Immunizations for Adolescents - Meningococcal		84.91%	R	Reported
Immunizations for Adolescents - Tdap		86.37%	R	Reported
Immunizations for Adolescents - HPV		37.47%	R	Reported
Immunizations for Adolescents - Combination 1		83.45%	R	Reported
Immunizations for Adolescents - Combination 2		35.52%	R	Reported
Lead Screening in Children (LSC)				
Lead Screening in Children		41.5%	R	Reported
Breast Cancer Screening (BCS)				
Breast Cancer Screening		40.82%	R	Reported
Cervical Cancer Screening (CCS)				
Cervical Cancer Screening		46.96%	R	Reported
Chlamydia Screening in Women (CHL)				
Chlamydia Screening in Women (16-20)		44.41%	R	Reported
Chlamydia Screening in Women (21-24)		54.66%	R	Reported
Chlamydia Screening in Women (Total)		49.36%	R	Reported
Appropriate Testing for Pharyngitis (CWP)				
Appropriate Testing for Pharyngitis (3-17)	Y	72.9%	R	Reported
Appropriate Testing for Pharyngitis (18-64)		64.32%	R	Reported
Appropriate Testing for Pharyngitis (65+)		0%	NA	Small Denominator
Appropriate Testing for Pharyngitis (Total)		69.63%	R	Reported
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)				
Use of Spirometry Testing in the Assessment and Diagnosis of COPD		23.48%	R	Reported
Pharmacotherapy Management of COPD Exacerbation (PCE)				
Pharmacotherapy Management of COPD Exacerbation - Systemic Corticosteroid	Y	41.47%	R	Reported
Pharmacotherapy Management of COPD Exacerbation - Bronchodilator		50.99%	R	Reported
Asthma Medication Ratio (AMR)				
Asthma Medication Ratio (5-11)	Y	80.19%	R	Reported
Asthma Medication Ratio (12-18)		65.52%	R	Reported
Asthma Medication Ratio (19-50)		58.1%	R	Reported
Asthma Medication Ratio (51-64)		59.15%	R	Reported

<i>Asthma Medication Ratio (Total)</i>		64.46%	R	Reported
Controlling High Blood Pressure (CBP)				
<i>Controlling High Blood Pressure</i>		51.09%	R	Reported
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	Y			
<i>Persistence of Beta-Blocker Treatment After a Heart Attack</i>		70.37%	R	Reported
Statin Therapy for Patients With Cardiovascular Disease (SPC)	Y			
<i>Statin Therapy for Patients With Cardiovascular Disease - Received Statin Therapy (M 21-75)</i>		65.41%	R	Reported
<i>Statin Therapy for Patients With Cardiovascular Disease - Statin Adherence 80% (M 21-75)</i>		63.91%	R	Reported
<i>Statin Therapy for Patients With Cardiovascular Disease - Received Statin Therapy (F 40-75)</i>		52.6%	R	Reported
<i>Statin Therapy for Patients With Cardiovascular Disease - Statin Adherence 80% (F 40-75)</i>		59.66%	R	Reported
<i>Statin Therapy for Patients With Cardiovascular Disease - Received Statin Therapy (Total)</i>		60.29%	R	Reported
<i>Statin Therapy for Patients With Cardiovascular Disease - Statin Adherence 80% (Total)</i>		62.43%	R	Reported
Cardiac Rehabilitation (CRE)				
<i>Cardiac Rehabilitation - Initiation (18-64)</i>		3.76%	R	Reported
<i>Cardiac Rehabilitation - Engagement1 (18-64)</i>		3.55%	R	Reported
<i>Cardiac Rehabilitation - Engagement2 (18-64)</i>		2.71%	R	Reported
<i>Cardiac Rehabilitation - Achievement (18-64)</i>		1.25%	R	Reported
<i>Cardiac Rehabilitation - Initiation (65+)</i>		0%	R	Reported
<i>Cardiac Rehabilitation - Engagement1 (65+)</i>		0%	R	Reported
<i>Cardiac Rehabilitation - Engagement2 (65+)</i>		0%	R	Reported
<i>Cardiac Rehabilitation - Achievement (65+)</i>		0%	R	Reported
<i>Cardiac Rehabilitation - Initiation (Total)</i>		3.47%	R	Reported
<i>Cardiac Rehabilitation - Engagement1 (Total)</i>		3.28%	R	Reported
<i>Cardiac Rehabilitation - Engagement2 (Total)</i>		2.51%	R	Reported
<i>Cardiac Rehabilitation - Achievement (Total)</i>		1.16%	R	Reported
Comprehensive Diabetes Care (CDC)				
<i>Comprehensive Diabetes Care - HbA1c Testing</i>		78.83%	R	Reported
<i>Comprehensive Diabetes Care - Poor HbA1c Control</i>		52.31%	R	Reported
<i>Comprehensive Diabetes Care - HbA1c Control (<8%)</i>		40.39%	R	Reported
<i>Comprehensive Diabetes Care - Eye Exams</i>		48.91%	R	Reported
<i>Comprehensive Diabetes Care - Blood Pressure Control (<140/90)</i>		45.74%	R	Reported
Kidney Health Evaluation for Patients With Diabetes (KED)				
<i>Kidney Health Evaluation for Patients With Diabetes (18-64)</i>		29.43%	R	Reported
<i>Kidney Health Evaluation for Patients With Diabetes (65-74)</i>		24.66%	R	Reported
<i>Kidney Health Evaluation for Patients With Diabetes (75-85)</i>		19.59%	R	Reported
<i>Kidney Health Evaluation for Patients With Diabetes (Total)</i>		28.72%	R	Reported
Statin Therapy for Patients With Diabetes (SPD)	Y			
<i>Statin Therapy for Patients With Diabetes - Received Statin Therapy</i>		47.74%	R	Reported
<i>Statin Therapy for Patients With Diabetes - Statin Adherence 80%</i>		60.95%	R	Reported
Antidepressant Medication Management (AMM)	Y			
<i>Antidepressant Medication Management - Effective Acute Phase Treatment</i>		56.48%	R	Reported
<i>Antidepressant Medication Management - Effective Continuation Phase Treatment</i>		39.81%	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD)	Y			
<i>Follow-Up Care for Children Prescribed ADHD Medication - Initiation Phase</i>		46.18%	R	Reported
<i>Follow-Up Care for Children Prescribed ADHD Medication - Continuation and Maintenance Phase</i>		57.23%	R	Reported
Follow-up After Hospitalization for Mental Illness (FUH)	Y			
<i>Follow-Up After Hospitalization For Mental Illness - 30 days (6-17)</i>		71.73%	R	Reported
<i>Follow-Up After Hospitalization For Mental Illness - 7 days (6-17)</i>		50.31%	R	Reported
<i>Follow-Up After Hospitalization For Mental Illness - 30 days (18-64)</i>		48.03%	R	Reported
<i>Follow-Up After Hospitalization For Mental Illness - 7 days (18-64)</i>		29.36%	R	Reported
<i>Follow-Up After Hospitalization For Mental Illness - 30 days (65+)</i>		32%	NA	Small Denominator
<i>Follow-Up After Hospitalization For Mental Illness - 7 days (65+)</i>		24%	NA	Small Denominator
<i>Follow-Up After Hospitalization For Mental Illness - 30 days (Total)</i>		51.94%	R	Reported

<i>Follow-Up After Hospitalization For Mental Illness - 7 days (Total)</i>		32.9%	R	Reported
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	Y			
<i>Follow-Up After Emergency Department Visit for Mental Illness - 30 days (6-17)</i>		75.72%	R	Reported
<i>Follow-Up After Emergency Department Visit for Mental Illness - 7 days (6-17)</i>		61.56%	R	Reported
<i>Follow-Up After Emergency Department Visit for Mental Illness - 30 days (18-64)</i>		55.33%	R	Reported
<i>Follow-Up After Emergency Department Visit for Mental Illness - 7 days (18-64)</i>		40.42%	R	Reported
<i>Follow-Up After Emergency Department Visit for Mental Illness - 30 days (65+)</i>		31.25%	NA	Small Denominator
<i>Follow-Up After Emergency Department Visit for Mental Illness - 7 days (65+)</i>		31.25%	NA	Small Denominator
<i>Follow-Up After Emergency Department Visit for Mental Illness - 30 days (Total)</i>		59.36%	R	Reported
<i>Follow-Up After Emergency Department Visit for Mental Illness - 7 days (Total)</i>		44.75%	R	Reported
Follow-Up After High-Intensity Care for Substance Use Disorder (FUJ)	Y			
<i>Follow-Up After High-Intensity Care for Substance Use Disorder - 30 days (13-17)</i>		50%	NA	Small Denominator
<i>Follow-Up After High-Intensity Care for Substance Use Disorder - 7 Days (13-17)</i>		50%	NA	Small Denominator
<i>Follow-Up After High-Intensity Care for Substance Use Disorder - 30 days (18-64)</i>		44.03%	R	Reported
<i>Follow-Up After High-Intensity Care for Substance Use Disorder - 7 Days (18-64)</i>		22.59%	R	Reported
<i>Follow-Up After High-Intensity Care for Substance Use Disorder - 30 days (65+)</i>		25%	NA	Small Denominator
<i>Follow-Up After High-Intensity Care for Substance Use Disorder - 7 Days (65+)</i>		0%	NA	Small Denominator
<i>Follow-Up After High-Intensity Care for Substance Use Disorder - 30 days (Total)</i>		43.85%	R	Reported
<i>Follow-Up After High-Intensity Care for Substance Use Disorder - 7 Days (Total)</i>		22.43%	R	Reported
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA)	Y			
<i>Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence - 30 days (13-17)</i>		13.56%	R	Reported
<i>Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence - 7 days (13-17)</i>		8.47%	R	Reported
<i>Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence - 30 days (18+)</i>		22.21%	R	Reported
<i>Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence - 7 days (18+)</i>		14.51%	R	Reported
<i>Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence - 30 days (Total)</i>		22.05%	R	Reported
<i>Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence - 7 days (Total)</i>		14.4%	R	Reported
Pharmacotherapy for Opioid Use Disorder (POD)	Y			
<i>Pharmacotherapy for Opioid Use Disorder (16-64)</i>		19.43%	R	Reported
<i>Pharmacotherapy for Opioid Use Disorder (65+)</i>		12.5%	NA	Small Denominator
<i>Pharmacotherapy for Opioid Use Disorder (Total)</i>		19.39%	R	Reported
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Med (SSD)	Y			
<i>Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications</i>		76.46%	R	Reported
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)				
<i>Diabetes Monitoring for People With Diabetes and Schizophrenia</i>		44.86%	R	Reported
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)				
<i>Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia</i>		57.69%	NA	Small Denominator
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	Y			
<i>Adherence to Antipsychotic Medications for Individuals With Schizophrenia</i>		52.72%	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)	Y			
<i>Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose Testing (1-11)</i>		39.38%	R	Reported
<i>Metabolic Monitoring for Children and Adolescents on Antipsychotics - Cholesterol Testing (1-11)</i>		24.92%	R	Reported
<i>Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose and Cholesterol Testing (1-11)</i>		23.69%	R	Reported
<i>Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose Testing (12-17)</i>		60.8%	R	Reported

Metabolic Monitoring for Children and Adolescents on Antipsychotics - Cholesterol Testing (12-17)		31.82%	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose and Cholesterol Testing (12-17)		31.06%	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose Testing (Total)		52.64%	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Cholesterol Testing (Total)		29.19%	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose and Cholesterol Testing (Total)		28.25%	R	Reported
Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)				
Non-Recommended Cervical Cancer Screening in Adolescent Females		0.59%	R	Reported
Appropriate Treatment for Upper Respiratory Infection (URI)				
Appropriate Treatment for Upper Respiratory Infection (3 Months-17 Years)	Y			
Appropriate Treatment for Upper Respiratory Infection (18-64)		88.04%	R	Reported
Appropriate Treatment for Upper Respiratory Infection (65+)		72.19%	R	Reported
Appropriate Treatment for Upper Respiratory Infection (Total)		98.8%	R	Reported
Appropriate Treatment for Upper Respiratory Infection (Total)		83.61%	R	Reported
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)				
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (3 Months-17 Years)	Y			
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (18-64)		59.3%	R	Reported
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (65+)		37.74%	R	Reported
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (Total)		93.48%	R	Reported
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (Total)		50.34%	R	Reported
Use of Imaging Studies for Low Back Pain (LBP)				
Use of Imaging Studies for Low Back Pain		75.98%	R	Reported
Use of Opioids at High Dosage (HDO)				
Use of Opioids at High Dosage	Y			
Use of Opioids at High Dosage		4.95%	R	Reported
Use of Opioids From Multiple Providers (UOP)				
Use of Opioids From Multiple Providers - Multiple Prescribers	Y			
Use of Opioids From Multiple Providers - Multiple Pharmacies		13.99%	R	Reported
Use of Opioids From Multiple Providers - Multiple Prescribers and Multiple Pharmacies		2.78%	R	Reported
Use of Opioids From Multiple Providers - Multiple Prescribers and Multiple Pharmacies		1.13%	R	Reported
Risk of Continued Opioid Use (COU)				
Risk of Continued Opioid Use - >=15 Days (18-64)	Y			
Risk of Continued Opioid Use - >=31 Days (18-64)		5.05%	R	Reported
Risk of Continued Opioid Use - >=15 Days (65+)		3.74%	R	Reported
Risk of Continued Opioid Use - >=31 Days (65+)		34.69%	R	Reported
Risk of Continued Opioid Use - >=15 Days (Total)		32.65%	R	Reported
Risk of Continued Opioid Use - >=31 Days (Total)		5.16%	R	Reported
Risk of Continued Opioid Use - >=15 Days (Total)		3.85%	R	Reported
Access/Availability of Care				
Adults' Access to Preventive/Ambulatory Health Services (AAP)				
Adults' Access to Preventive/Ambulatory Health Services (20-44)		70.53%	R	Reported
Adults' Access to Preventive/Ambulatory Health Services (45-64)		78.11%	R	Reported
Adults' Access to Preventive/Ambulatory Health Services (65+)		84.37%	R	Reported
Adults' Access to Preventive/Ambulatory Health Services (Total)		73.78%	R	Reported
Annual Dental Visit (ADV)				
Annual Dental Visit (2-3)	Y			
Annual Dental Visit (4-6)		46%	R	Reported
Annual Dental Visit (7-10)		61.25%	R	Reported
Annual Dental Visit (11-14)		63.91%	R	Reported
Annual Dental Visit (15-18)		59.54%	R	Reported
Annual Dental Visit (19-20)		51.98%	R	Reported
Annual Dental Visit (Total)		34.28%	R	Reported
Annual Dental Visit (Total)		56.07%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET)				
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Alcohol Abuse or Dependence (13-17)	Y			
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Alcohol Abuse or Dependence (13-17)		31.76%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Alcohol Abuse or Dependence (13-17)		10.59%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Alcohol Abuse or Dependence (13-17)		57.14%	NA	Small Denominator
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Opioid Abuse or Dependence (13-17)		28.57%	NA	Small Denominator

Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Other Drug Abuse or Dependence (13-17)		46.58%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Other Drug Abuse or Dependence (13-17)		14.1%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Total (13-17)		42.81%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Total (13-17)		13.7%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Alcohol Abuse or Dependence (18+)		41.4%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Alcohol Abuse or Dependence (18+)		13.54%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Opioid Abuse or Dependence (18+)		57.46%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Opioid Abuse or Dependence (18+)		25.49%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Other Drug Abuse or Dependence (18+)		43.15%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Other Drug Abuse or Dependence (18+)		12.56%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Total (18+)		43.8%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Total (18+)		15.34%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Alcohol Abuse or Dependence (Total)		41.22%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Alcohol Abuse or Dependence (Total)		13.49%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Opioid Abuse or Dependence (Total)		57.46%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Opioid Abuse or Dependence (Total)		25.5%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Other Drug Abuse or Dependence (Total)		43.33%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Other Drug Abuse or Dependence (Total)		12.64%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Total (Total)		43.77%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Total (Total)		15.3%	R	Reported
Prenatal and Postpartum Care (PPC)				
Prenatal and Postpartum Care - Timeliness of Prenatal Care		79.32%	R	Reported
Prenatal and Postpartum Care - Postpartum Care		67.4%	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)				
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (1-11)	Y	66.06%	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (12-17)		60.69%	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Total)		62.77%	R	Reported
Utilization				
Well-Child Visits in the First 30 Months of Life (W30)				
Well-Child Visits in the First 30 Months of Life (First 15 Months)		56.89%	R	Reported
Well-Child Visits in the First 30 Months of Life (15 Months-30 Months)		67.1%	R	Reported
Child and Adolescent Well-Care Visits (WCV)				
Child and Adolescent Well-Care Visits (3-11)		44.51%	R	Reported
Child and Adolescent Well-Care Visits (12-17)		35.28%	R	Reported
Child and Adolescent Well-Care Visits (18-21)		14.81%	R	Reported
Child and Adolescent Well-Care Visits (Total)		37.27%	R	Reported
Frequency of Selected Procedures (FSP)				
Ambulatory Care (AMBa)			R	Reported
Ambulatory Care (AMBb)			NR	Not Reported
Ambulatory Care (AMBc)			NR	Not Reported

Ambulatory Care (AMBd)			NR	Not Reported
Inpatient Utilization - General Hospital/Acute Care (IPUa)			R	Reported
Inpatient Utilization - General Hospital/Acute Care (IPUb)			NR	Not Reported
Inpatient Utilization - General Hospital/Acute Care (IPUc)			NR	Not Reported
Inpatient Utilization - General Hospital/Acute Care (IPUd)			NR	Not Reported
Identification of Alcohol and other Drug Services (IADa)	Y		R	Reported
Identification of Alcohol and other Drug Services (IADb)			NR	Not Reported
Identification of Alcohol and other Drug Services (IADc)			NR	Not Reported
Identification of Alcohol and other Drug Services (IADd)			NR	Not Reported
Mental Health Utilization (MPTa)	Y		R	Reported
Mental Health Utilization (MPTb)			NR	Not Reported
Mental Health Utilization (MPTc)			NR	Not Reported
Mental Health Utilization (MPTd)			NR	Not Reported
Antibiotic Utilization (ABXa)	Y		R	Reported
Antibiotic Utilization (ABXb)			NR	Not Reported
Antibiotic Utilization (ABXc)			NR	Not Reported
Antibiotic Utilization (ABXd)			NR	Not Reported
Risk Adjusted Utilization				
Plan All-Cause Readmissions (PCR)			R	Reported
Health Plan Descriptive Information				
Enrollment by Product Line (ENPa)			R	Reported
Enrollment by Product Line (ENPb)			NR	Not Reported
Enrollment by Product Line (ENPc)			NR	Not Reported
Enrollment by Product Line (ENPd)			NR	Not Reported
Enrollment by State (EBS)			R	Reported
Language Diversity of Membership (LDM)			NR	Not Reported
Race/Ethnicity Diversity of Membership (RDM)			NR	Not Reported
Total Membership (TLM)			NR	Not Reported
Electronic Clinical Data Systems				
Breast Cancer Screening (BCS-E)				
<i>Breast Cancer Screening</i>			NR	Not Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)				
<i>Follow-Up Care for Children Prescribed ADHD Medication - Initiation Phase</i>			NR	Not Reported
<i>Follow-Up Care for Children Prescribed ADHD Medication - Continuation and Maintenance Phase</i>			NR	Not Reported
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)				
<i>Depression Screening and Follow-Up for Adolescents and Adults - Depression Screening (Total)</i>			NR	Not Reported
<i>Depression Screening and Follow-Up for Adolescents and Adults - Follow-up on Positive Screen (Total)</i>			NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)				
<i>Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults - Utilization of PHQ-9-Period1 (Total)</i>			NR	Not Reported
<i>Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults - Utilization of PHQ-9-Period2 (Total)</i>			NR	Not Reported
<i>Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults - Utilization of PHQ-9-Period3 (Total)</i>			NR	Not Reported
<i>Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults - Utilization of PHQ-9-Total (Total)</i>			NR	Not Reported
Depression Remission or Response for Adolescents and Adults (DRR-E)				
<i>Depression Remission or Response for Adolescents and Adults - Follow-up PHQ-9 (Total)</i>			NR	Not Reported
<i>Depression Remission or Response for Adolescents and Adults - Depression Remission (Total)</i>			NR	Not Reported
<i>Depression Remission or Response for Adolescents and Adults - Depression Response (Total)</i>			NR	Not Reported
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)				
<i>Unhealthy Alcohol Use Screening and Follow-Up - Unhealthy Alcohol Use Screening (Total)</i>			NR	Not Reported
<i>Unhealthy Alcohol Use Screening and Follow-Up - Alcohol Counseling or Other Follow-Up Care (Total)</i>			NR	Not Reported
Adult Immunization Status (AIS-E)				
<i>Adult Immunization Status - Influenza</i>			NR	Not Reported
<i>Adult Immunization Status - Td/Tdap</i>			NR	Not Reported
<i>Adult Immunization Status - Zoster</i>			NR	Not Reported
Prenatal Immunization Status (PRS-E)				
<i>Prenatal Immunization Status - Influenza</i>			NR	Not Reported
<i>Prenatal Immunization Status - Tdap</i>			NR	Not Reported
<i>Prenatal Immunization Status - Combination</i>			NR	Not Reported

Prenatal Depression Screening and Follow-Up (PND-E)				
<i>Prenatal Depression Screening and Follow-Up - Depression Screening</i>			NR	Not Reported
<i>Prenatal Depression Screening and Follow-Up - Follow-Up on Positive Screen</i>			NR	Not Reported
Postpartum Depression Screening and Follow-Up (PDS-E)				
<i>Postpartum Depression Screening and Follow-Up - Depression Screening</i>			NR	Not Reported
<i>Postpartum Depression Screening and Follow-Up - Follow-Up on Positive Screen</i>			NR	Not Reported